| Literature DB >> 27748080 |
Kirsten A M White1, Li Luo1, Todd A Thompson2, Salina Torres3, Chien-An Andy Hu4, Nancy E Thomas5,6, Jenna Lilyquist1, Hoda Anton-Culver7, Stephen B Gruber8, Lynn From9, Klaus J Busam10, Irene Orlow10, Peter A Kanetsky11, Loraine D Marrett9, Richard P Gallagher12, Lidia Sacchetto13, Stefano Rosso13, Terence Dwyer14, Anne E Cust15, Colin B Begg10, Marianne Berwick1.
Abstract
Autophagy has been linked with melanoma risk and survival, but no polymorphisms in autophagy-related (ATG) genes have been investigated in relation to melanoma progression. We examined five single-nucleotide polymorphisms (SNPs) in three ATG genes (ATG5; ATG10; and ATG16L) with known or suspected impact on autophagic flux in an international population-based case-control study of melanoma. DNA from 911 melanoma patients was genotyped. An association was identified between (GG) (rs2241880) and earlier stage at diagnosis (OR 0.47; 95% Confidence Intervals (CI) = 0.27-0.81, P = 0.02) and a decrease in Breslow thickness (P = 0.03). The ATG16L heterozygous genotype (AG) (rs2241880) was associated with younger age at diagnosis (P = 0.02). Two SNPs in ATG5 were found to be associated with increased stage (rs2245214 CG, OR 1.47; 95% CI = 1.11-1.94, P = 0.03; rs510432 CC, OR 1.84; 95% CI = 1.12-3.02, P = 0.05). Finally, we identified inverse associations between ATG5 (GG rs2245214) and melanomas on the scalp or neck (OR 0.20, 95% CI = 0.05-0.86, P = 0.03); ATG10 (CC) (rs1864182) and brisk tumor infiltrating lymphocytes (TILs) (OR 0.42; 95% CI = 0.21-0.88, P = 0.02), and ATG5 (CC) (rs510432) with nonbrisk TILs (OR 0.55; 95% CI = 0.34-0.87, P = 0.01). Our data suggest that ATG SNPs might be differentially associated with specific host and tumor characteristics including age at diagnosis, TILs, and stage. These associations may be critical to understanding the role of autophagy in cancer, and further investigation will help characterize the contribution of these variants to melanoma progression.Entities:
Keywords: zzm321990ATG16L1zzm321990; zzm321990SNPzzm321990; autophagy; melanoma; polymorphism
Mesh:
Substances:
Year: 2016 PMID: 27748080 PMCID: PMC5119988 DOI: 10.1002/cam4.929
Source DB: PubMed Journal: Cancer Med ISSN: 2045-7634 Impact factor: 4.452
Clinicopathologic characteristics among 911 melanoma cases
| Characteristic | No.(%) | |
|---|---|---|
| Median age at diagnosis | 60 years | |
| Median Breslow thickness | 0.8 mm | |
| Gender | ||
| Male | 534 (59) | |
| Female | 377 (41) | |
| Breslow thickness (mm) | ||
| 0.01–1.00 | 547 (60) | |
| 1.01–2.00 | 212 (23) | |
| 2.01–4.00 | 108 (12) | |
| >4.00 | 44 (5) | |
| Status | ||
| Single primary | 603 (66) | |
| Multiple primary | 308 (34) | |
| Anatomic site | ||
| Trunk/pelvis | 394 (43) | |
| Scalp/neck | 56 (6) | |
| Face/ears/other | 116 (13) | |
| Upper extremities | 172 (19) | |
| Lower extremities | 173 (19) | |
| Histological subtype | ||
| Superficial Spreading Melanoma | 610 (67) | |
| Nodular Melanoma | 92 (10) | |
| Lentigo Maligna Melanoma | 116 (13) | |
| Other | 93 (10) | |
| Ulceration | ||
| Absent | 794 (92) | |
| Present | 73 (8) | |
| Missing | 44 (0) | |
| Mitosis | ||
| Absent | 454 (52) | |
| Present | 415 (48) | |
| Missing | 42 (0) | |
| AJCC stage | ||
| T1a | 397 (46) | |
| T1b | 124 (14) | |
| T2a | 183 (21) | |
| T2b | 16 (2) | |
| T3a | 73 (8) | |
| T3b | 32 (4) | |
| T4a | 21 (2) | |
| T4b | 21 (2) | |
| AJCC stage (T1a/T1b/T2a vs. T2b+) | ||
| T1a/T1b/T2a | 704 (81) | |
| T2b+ | 163 (19) | |
| TIL grade | ||
| Absent | 194 (22) | |
| Non‐Brisk | 563 (65) | |
| Brisk | 111 (13) | |
| Missing | 43 (0) | |
| Growth phase | ||
| Absent | 255 (29) | |
| Present | 614 (71) | |
| Missing | 42 (0) | |
| Death from melanoma | 76 (8) | |
| Alive or death from other causes | 835 (92) | |
AJCC, American Joint Committee on Cancer; TIL, Tumor infiltrating lymphocytes; *Death from melanoma recorded during 7.5 years of follow‐up.
Figure 1Overview of the Autophagy related (ATG) conjugation pathway including significant associations with SNPs investigated in this study, including those in the ATG5, ATG10 and ATG16L genes.
Genotypic frequencies of ATG gene polymorphisms tested in melanoma cases
|
| Genotype | Number of patients (%) |
|---|---|---|
|
| ||
| rs510432 | CC | 190 (0.22) |
| CT | 425 (0.48) | |
| TT | 266 (0.30) | |
| Missing | 30 | |
|
| ||
| rs2245214 | CC | 331 (0.38) |
| CG | 427 (0.49) | |
| GG | 110 (0.13) | |
| Missing | 43 | |
|
| ||
| rs2241880 | AA | 198 (0.23) |
| AG | 418 (0.490 | |
| GG | 245 (0.29) | |
| Missing | 50 | |
|
| ||
| rs10514231 | CC | 116 (0.13) |
| CT | 403 (0.47) | |
| TT | 345 (0.40) | |
| Missing | 47 | |
|
| ||
| rs1864182 | AA | 238 (0.28) |
| AC | 424 (0.49) | |
| CC | 200 (0.23) | |
| Missing | 49 | |
Associated clinicopathologic characteristics by genotype status among melanoma cases
| Age at diagnosis, y | |||||
|---|---|---|---|---|---|
|
| Genotype |
| Coeff (95% CI) |
| Global |
| rs10514231 | TT | 864 | 1.00 | ||
| CT | 0.22 (−1.95–2.39) | 0.84 | 0.71 | ||
| CC | 1.33 (−1.84–4.50) | 0.41 | |||
| rs1864182 | AA | 862 | 1.00 | ||
| AC | 0.72 (−1.67–3.11) | 0.55 | 0.70 | ||
| CC | −0.26 (−3.09–2.57) | 0.86 | |||
| rs2241880 | AA | 861 | 1.00 | ||
| AG | −3.25 (−5.60–0.91) |
|
| ||
| GG | −2.04 (−4.83–0.74) | 0.15 | |||
| rs2245214 | CC | 868 | 1.00 | ||
| CG | −0.59 (−2.77–1.58) | 0.59 | 0.75 | ||
| GG | −1.17 (−4.43–2.09) | 0.48 | |||
| rs510432 | TT | 881 | 1.00 | ||
| CT | 0.43 (−1.86–2.73) | 0.71 | 0.75 | ||
| CC | −0.55 (−3.33–2.23) | 0.70 | |||
CI, confidence interval; Coeff, coefficient; *P < .05 were considered significant; Bolded results indicate significant associations.
Genotypic model adjusted for gender, study center. and status.
Genotypic model adjusted for age (continuous), gender, study center, and status.
Relationship Between ATG Genotype and AJCC Stage in Melanoma
| Melanoma Stage(≥ Stage T2b vs. Stage T1a/T1b/T2a) | ||||
|---|---|---|---|---|
|
| Genotype | ≥ Stage T2b versus Stage T1a/T1b/T2a |
| Global |
| rs10514231 | TT | 1.00 | ||
| CT | 1.18 (0.80–1.76) | 0.41 | 0.46 | |
| CC | 0.84 (0.46–1.54) | 0.57 | ||
| rs1864182 | AA | 1.00 | ||
| AC | 1.22 (0.79–1.89) | 0.38 | 0.52 | |
| CC | 0.98 (0.57–1.66) | 0.93 | ||
| rs2241880 | AA | 1.00 | ||
| AG | 0.88 (0.59–1.33) | 0.55 |
| |
| GG | 0.47 (0.27–0.81) |
| ||
| rs2245214 | CC | 1.00 | ||
| CG | 1.46 (0.98–2.17) | 0.06 | 0.14 | |
| GG | 1.05 (0.57–1.92) | 0.88 | ||
| rs510432 | TT | 1.00 | ||
| CT | 1.26 (0.81–1.95) | 0.30 |
| |
| CC | 1.84 (1.12–3.02) |
| ||
Genotypic model adjusted for age (continuous), gender, study center, and status. Abbreviations: AJCC, American Joint Committee on Cancer; *P values < .05 were considered significant; Bolded results indicate significant associations.